Insider Transactions in Q2 2024 at Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Yuval Cohen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
22,938
-6.35%
|
$963,396
$42.24 P/Share
|
|
Jun 18
2024
|
Yuval Cohen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,759
+5.15%
|
$252,144
$16.12 P/Share
|
|
Jun 18
2024
|
Sean F. Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,958
-3.87%
|
$82,236
$42.12 P/Share
|
|
Jun 18
2024
|
Sean F. Moran Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,958
+3.73%
|
$58,740
$30.0 P/Share
|
|
Jun 17
2024
|
Yuval Cohen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,103
-6.01%
|
$510,738
$46.02 P/Share
|
|
Jun 17
2024
|
Yuval Cohen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,103
+5.53%
|
$188,751
$17.13 P/Share
|
|
Jun 17
2024
|
Sean F. Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,730
-12.16%
|
$309,580
$46.77 P/Share
|
|
Jun 17
2024
|
Sean F. Moran Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,730
+10.84%
|
$94,220
$14.1 P/Share
|
|
Jun 14
2024
|
Yuval Cohen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,317
-14.76%
|
$1,465,850
$50.17 P/Share
|
|
Jun 14
2024
|
Yuval Cohen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,317
+12.84%
|
$263,853
$9.18 P/Share
|
|
Jun 14
2024
|
Sean F. Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,355
-8.47%
|
$458,395
$49.87 P/Share
|
|
Jun 14
2024
|
Sean F. Moran Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,355
+7.58%
|
$159,035
$17.13 P/Share
|
|
Jun 14
2024
|
Alan F Holmer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+22.24%
|
$50,010
$30.0 P/Share
|
|
May 30
2024
|
Peter Salzmann |
BUY
Grant, award, or other acquisition
|
Direct |
2,783
+50.0%
|
-
|
|
May 30
2024
|
Avery W Catlin |
BUY
Grant, award, or other acquisition
|
Direct |
2,783
+39.02%
|
-
|
|
May 30
2024
|
John Kenneth Jenkins |
BUY
Grant, award, or other acquisition
|
Direct |
2,783
+49.71%
|
-
|
|
May 30
2024
|
Anne Altmeyer |
BUY
Grant, award, or other acquisition
|
Direct |
2,783
+50.0%
|
-
|
|
May 30
2024
|
Alan F Holmer |
BUY
Grant, award, or other acquisition
|
Direct |
2,783
+40.07%
|
-
|
|
May 30
2024
|
Ben Yong |
BUY
Grant, award, or other acquisition
|
Direct |
2,783
+50.0%
|
-
|
|
May 30
2024
|
Rachelle Suzanne Jacques |
BUY
Grant, award, or other acquisition
|
Direct |
2,783
+50.0%
|
-
|
|
Apr 10
2024
|
Sean F. Moran Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,787
+3.55%
|
$53,610
$30.0 P/Share
|